Literature DB >> 35558263

Large population-based study of upper tract urothelial carcinoma in China may provide further insight into the impact of bladder cancer on upper tract urothelial carcinoma's prognosis in Chinese population.

Shuxiong Zeng1, Zhensheng Zhang1, Chuanliang Xu1.   

Abstract

Entities:  

Year:  2022        PMID: 35558263      PMCID: PMC9085925          DOI: 10.21037/tau-2022-01

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN: 2223-4683


× No keyword cloud information.
We appreciate the comment on our study on impact of previous, simultaneous or intravesical recurrence bladder cancer on prognosis of upper tract urothelial carcinoma (UTUC) after nephroureterectomy (1). We agree with Li and Chung that the incidence, carcinogenic factors, pathological characteristics of UTUC may differ between China and the U.S. For examples, it is reported that UTUC tends to be more female predominant in China, while it is more prevalent in males in the U.S. or European countries (2,3). Furthermore, tobacco smoking is a predominant risk factor for UTUC in the Western countries, but less than one fifth had this exposure in China (3). The use of traditional Chinese medicine containing aristolochic acid was more prevalent among Chinese, especially for female, and this may explain the observed gender differences among Chinese with UTUC (4-6). Moreover, UTUC tumors were found be more located in the ureter than in the renal pelvis (2). Several studies have revealed some distinctive prognostic factors to the Chinese population such as gender (3), tumor location (2,7) and aristolochic acid mutational signature (5). Regarding several concerns raised in the comment, our reply may perhaps clarify some of them. We agree on that the chronic kidney disease (CKD) stage and dialysis history, regimens of intravesical chemotherapy and follow-up schedule play important roles in the prognosis of UTUC. Apart from these parameters mentioned by Li and Chung, smoking history, diagnostic ureteroscopy, neoadjuvant or adjuvant chemotherapy that potentially have impact on the intravesical recurrence and survival are also absent in the SEER database. As a result, we were unable to balance these factors among groups in our analysis, and this was mentioned as the major limitations in our manuscript. Although it was reported that CKD was associated with worse overall survival, CKD had no effect on the cancer specific survival (CSS) (4,8,9). Since the primary outcome of the present study focused on CSS, CKD may not influence the conclusions of the present study. The present study is based on database from the U.S., some of our outcomes are in line with previous studies from Asian’ cohort with large sample size (10). Furthermore, as with many registry-based retrospective studies, screening guidelines, surgical techniques, management patterns and follow-up schedules were unable to be standardized. Realistically, however, this heterogeneity reflects the variations of clinical practice in the real-world setting, and this may increase the generalizability of our results. Moreover, the conclusions of our study are strengthened by its large sample size and statistical method we used to balance the baseline and pathological factors that had significantly impact on the CSS of UTUC. Future study with large sample size and detailed clinicopathological information from national-wide cooperation in China may provide further insight into the characteristics of UTUC in Chinese population. The article’s supplementary files as
  10 in total

1.  A Multi-Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States.

Authors:  Nirmish Singla; Dong Fang; Xiaohong Su; Zhengqing Bao; Zhenpeng Cao; Syed M Jafri; Gengyan Xiong; Lei Zhang; Ryan Hutchinson; Arthur Sagalowsky; Yair Lotan; Xuesong Li; Liqun Zhou; Jay D Raman; Vitaly Margulis
Journal:  J Urol       Date:  2016-11-22       Impact factor: 7.450

2.  Development and external validation of a nomogram predicting prognosis of upper tract urothelial carcinoma after radical nephroureterectomy.

Authors:  Shuxiong Zeng; Lihe Dai; Jun Yang; Xiaomin Gao; Xiaowen Yu; Qian Ren; Kaijian Wang; Jinshan Xu; Zeyu Yang; Bo Yang; Huiqing Wang; Qing Yang; Huamao Ye; Jianguo Hou; Yue Pan; Zhensheng Zhang; Zhiliang Weng; Yinghao Sun; Chuanliang Xu
Journal:  Urol Oncol       Date:  2019-01-08       Impact factor: 3.498

3.  Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high-volume centre in China.

Authors:  Xiao-Peng Chen; Geng-Yan Xiong; Xue-Song Li; Surena F Matin; Maurice Garcia; Dong Fang; Tian-Yu Wang; Wei Yu; Kan Gong; Yi Song; Zhi-Song He; Qun He; Li-Qun Zhou
Journal:  BJU Int       Date:  2013-07-26       Impact factor: 5.588

4.  Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma.

Authors:  Kentaro Kuroiwa; Junichi Inokuchi; Hiroyuki Nishiyama; Takahiro Kojima; Yoshiyuki Kakehi; Mikio Sugimoto; Toshiki Tanigawa; Hiroyuki Fujimoto; Momokazu Gotoh; Naoya Masumori; Osamu Ogawa; Masatoshi Eto; Chikara Ohyama; Akira Yokomizo; Hideyasu Matsuyama; Tomohiko Ichikawa; Junki Mizusawa; Junko Eba; Seiji Naito
Journal:  J Urol       Date:  2019-06-28       Impact factor: 7.450

5.  CKD as a risk factor for bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma.

Authors:  Shiu-Dong Chung; Kuo-How Huang; Ming-Kuen Lai; Chao-Yuan Huang; Chung-Hsin Chen; Yeong-Shiau Pu; Hong-Jeng Yu; Shih-Chieh Chueh
Journal:  Am J Kidney Dis       Date:  2007-11       Impact factor: 8.860

6.  Aristolochic acid containing herbs induce gender-related oncological differences in upper tract urothelial carcinoma patients.

Authors:  Gengyan Xiong; Lin Yao; Peng Hong; Li Yang; Weimin Ci; Libo Liu; Qun He; Kan Gong; Xuesong Li; Liqun Zhou
Journal:  Cancer Manag Res       Date:  2018-12-04       Impact factor: 3.989

7.  Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies.

Authors:  Yu-Chan Kang; Ming-Hong Chen; Chung-Ying Lin; Chih-Yun Lin; Yen-Ta Chen
Journal:  Ther Adv Drug Saf       Date:  2021-03-21

8.  Impact of previous, simultaneous or intravesical recurrence bladder cancer on prognosis of upper tract urothelial carcinoma after nephroureterectomy: a large population-based study.

Authors:  Shuxiong Zeng; Yidie Ying; Xiaowen Yu; Linhui Wang; Zhensheng Zhang; Chuanliang Xu
Journal:  Transl Androl Urol       Date:  2021-12

9.  Propensity-Matched Survival Analysis of Upper Urinary Tract Urothelial Carcinomas between End-Stage Renal Disease with and without Kidney Transplantation.

Authors:  Hao Lun Luo; Po Hui Chiang; Yuan Tso Cheng; Yen Ta Chen
Journal:  Biomed Res Int       Date:  2019-04-01       Impact factor: 3.411

10.  Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.

Authors:  Huan Lu; Yuan Liang; Bao Guan; Yue Shi; Yanqing Gong; Juan Li; Wenwen Kong; Jin Liu; Dong Fang; Libo Liu; Qun He; Muhammad Shakeel; Xuesong Li; Liqun Zhou; Weimin Ci
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.